JHDD-developed glutamine antagonist receives Fast Track designation from FDA for small-cell lung cancer
JHDD-cofounded PSMA Therapeutics acquired by Bayer AG
JHDD coauthors a report showing glutamine antagonism overcomes tumor immune invasion [Science]
JHDD received a UG3 grant through the HEAL initiative to develop new a new treatment for neuropathic pain
Our high throughput screening collaboration with Eisai represents an innovative way to create synergy between complimentary organizations to develop new therapeutics.